跳至主要内容
临床试验/NCT02658461
NCT02658461已完成不适用

Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)

Hoffmann-La Roche0 个研究点目标入组 36 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
36
主要终点
Monetary Cost of Health Care Resources Used Per Episode of Care in Administration of Trastuzumab SC Injection

研究概览

简要总结

This prospective, non-interventional time and motion study will evaluate the costs of healthcare resource utilization associated with the administration of trastuzumab (Herceptin) SC and IV formulations in HER2-positive EBC. This is a sub-study of the clinical study MO22982 (NCT01401166/PrefHer).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participants from the MO22982 (PrefHer) clinical trial who consent to the presence of an observer to record data for the study during administration of trastuzumab
  • Members of the care team responsible for management of participants from the MO22982 (PrefHer) clinical trial who also consent to the presence of an observer during administration of trastuzumab

排除标准

  • None specified

研究组 & 干预措施

Trastuzumab IV Infusion

Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.

干预措施: Trastuzumab (Drug)

Trastuzumab SC Single-Use Injection Device

Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.

干预措施: Trastuzumab (Drug)

Trastuzumab SC Vial/Syringe

Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.

干预措施: Trastuzumab (Drug)

结局指标

主要结局

Monetary Cost of Health Care Resources Used Per Episode of Care in Administration of Trastuzumab SC Injection

时间窗: Data collection up to 1 year

The study observed 36 episodes of care (12 per study arm) to collect data on infusion/injection-related tasks. HCP time was estimated using hourly salary data from NHS reference costs. Consumable supplies were costed using hospital pharmacy data and online sources. Analysis was limited to only those items with an individual cost of £0.05 or more. Monetary cost of health care resources was determined by adding the costs of consumable supplies and HCP time spent in the administration of trastuzumab SC injection during a single episode of care. The average monetary cost per episode was calculated and expressed in pounds.

Monetary Cost of Health Care Resources Used Per Episode of Care in Administration of Trastuzumab Single-Use Injection Device

时间窗: Data collection up to 1 year

The study observed 36 episodes of care (12 per study arm) to collect data on infusion/injection-related tasks. HCP time was estimated using hourly salary data from National Health Service (NHS) reference costs. Consumable supplies were costed using hospital pharmacy data and online sources. Analysis was limited to only those items with an individual cost of £0.05 or more. Monetary cost of health care resources was determined by adding the costs of consumable supplies and HCP time spent in the administration of trastuzumab single-use injection device during a single episode of care. The average monetary cost per episode was calculated and expressed in pounds.

次要结局

  • Total HCP Time Required Per Episode of Care in the Preparation of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Number of Consumable Medical Supplies Used Per Episode of Care in the Preparation of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Task-Specific HCP Time Required Per Episode of Care in the Administration of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Task-Specific HCP Time Required Per Episode of Care in the Preparation of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Total HCP Time Required Per Episode of Care in the Administration of Trastuzumab SC Injection(Data collection up to 1 year)
  • Total HCP Time Required Per Episode of Care in the Administration of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Number of Consumable Medical Supplies Used Per Episode of Care in the Administration of Trastuzumab Single-Use Injection Device(Data collection up to 1 year)
  • Number of Consumable Medical Supplies Used Per Episode of Care in the Administration of Trastuzumab SC Injection(Data collection up to 1 year)
  • Number of Consumable Medical Supplies Used Per Episode of Care in the Administration of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Monetary Cost of Health Care Resources Used Per Episode of Care in Preparation and Administration of Trastuzumab IV Infusion(Data collection up to 1 year)
  • Task-Specific HCP Time Required Per Episode of Care in the Administration of Trastuzumab Single-Use Injection Device(Data collection up to 1 year)
  • Task-Specific HCP Time Required Per Episode of Care in the Administration of Trastuzumab SC Injection(Data collection up to 1 year)
  • Total HCP Time Required Per Episode of Care in the Administration of Trastuzumab Single-Use Injection Device(Data collection up to 1 year)
  • Total Participant Time Per Episode of Care Spent in the Care Unit for Administration of Trastuzumab(Data collection up to 1 year)
  • Total Participant Time Per Episode of Care Spent in the Chair for Administration of Trastuzumab(Data collection up to 1 year)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验